Latest Breaking News On - ரோஜர் பேர்ல்முத்தேர் - Page 3 : comparemela.com

Article content A machine learning start-up that is aiming to speed up drug discovery and shake up the pharmaceutical industry has raised US$400 milllion from investors including, the Canadian Plan Investment Board, SoftBank and Temasek. Insitro, which is run by former Stanford artificial intelligence professor Daphne Koller, has partnerships with Gilead Sciences and Bristol-Myers Squibb to discover new biological targets for drug treatments, and the drugs themselves. We apologize, but this video has failed to load. Try refreshing your browser, or CPPIB leads group investing $400-million in startup that can crack open genetic drivers of diseases Back to video The pandemic has given investors hope that the long and costly timelines for discovering drugs often as long as 10 years can be slashed using new technology. The funding round, which is led by the CPPIB, also includes further investment from existing investors such as Andreessen Horowitz, T Rowe Price and BlackRock

United statesPaul mccrackenRoger perlmutterHannah kuchlerDaphne kollerAndreessen horowitzEli lillyBristol myers squibbFinancial times ltdHaystack sciencesGilead sciencesPostmedia network incCanadian plan investment boardBig pharmaFinancial timesPostmedia network